Close

UPDATE: DarioHealth Corp. (DRIO) PT Lowered to $25 at Stifel, Following Earnings Miss

May 18, 2021 3:27 PM EDT
Get Alerts DRIO Hot Sheet
Price: $1.47 -3.29%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
(Updated - May 19, 2021 7:16 AM EDT)

Stifel analyst David M. Grossman lowered the price target on DarioHealth Corp. (NASDAQ: DRIO) to $25.00 (from $30.00) after the company reported 1Q21 results that missed expectations with Revenue within $0.1mn of the Stifel estimate but the EBITDA loss higher. Management does not provide guidance, so consensus is in a wide range and less indicative of what the company is expecting.

The analyst reiterated a Buy rating, stating "The company also announced the acquisition of behavioral health provider wayForward, which we view positively as the company executes its strategy to provide a comprehensive digital health solution to the enterprise market. It is still early in the enterprise sales cycle (closes Aug/Sept); however, the company expects to sign at least one health plan in 2Q and potentially another employer or provider. 2021 is a transitional year, which creates near-term forecasting challenges, and we are lowering our 2021 revenue forecast to reduce dependence on 2H. That said, fundamentally the company is doing the right things to create a digital health platform purpose built for the enterprise market and remains attractive at 7x 2022 revenues."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Stifel, Earnings, Definitive Agreement